<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04775797</url>
  </required_header>
  <id_info>
    <org_study_id>AB-836-001</org_study_id>
    <nct_id>NCT04775797</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Pharmacokinetics of AB-836 in Healthy Subjects and Subjects With Chronic HBV Infection</brief_title>
  <official_title>A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple Dose Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AB-836, an HBV Capsid Inhibitor, in Healthy Subjects and Subjects With Chronic HBV Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arbutus Biopharma Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arbutus Biopharma Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This three-part, Phase 1 protocol will be the first clinical study of AB-836. Parts 1 and 2&#xD;
      will be a Phase 1a SAD/MAD of AB-836 in healthy adult subjects. Part 3 will be a Phase 1b&#xD;
      dose-ranging assessment of AB-836 in non-cirrhotic Chronic Hepatitis B (CHB) subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 25, 2021</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of TEAEs</measure>
    <time_frame>Up to 28 days after last dose of AB-836/placebo</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of discontinuations due to AEs</measure>
    <time_frame>Up to 28 days after last dose of AB-836/placebo</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of lab abnormalities</measure>
    <time_frame>Up to 28 days after last dose of AB-836/placebo</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Chronic Hepatitis</condition>
  <arm_group>
    <arm_group_label>Part 1 (Healthy Subjects): Single Ascending Dose (SAD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two cohorts (Cohorts A and B) of healthy subjects will receive single doses of AB-836/placebo in an alternating cohort design under fasted conditions. One additional treatment will be administered under fed conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 (Healthy Subjects): Multiple Ascending Dose (MAD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in Cohorts C, D and E will receive a once daily dose of AB-836/placebo for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3 (Chronic Hepatitis B [CHB] Participants): MAD Cohorts F-H</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in Cohorts F, G, and H will receive multiple doses of AB-836/placebo once daily for 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3 (Chronic Hepatitis B [CHB] Participants): MAD Cohort I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in Cohort I will receive multiple doses of AB-836/placebo once daily for 28 days in combination with ongoing nucleos(t)ide analog (NA) therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3 (Chronic Hepatitis B [CHB] Participants): MAD Cohort J</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in Cohort J will receive AB-836/placebo and TDF in combination once daily for 28 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AB-836</intervention_name>
    <description>Capsules or Tablets</description>
    <arm_group_label>Part 1 (Healthy Subjects): Single Ascending Dose (SAD)</arm_group_label>
    <arm_group_label>Part 2 (Healthy Subjects): Multiple Ascending Dose (MAD)</arm_group_label>
    <arm_group_label>Part 3 (Chronic Hepatitis B [CHB] Participants): MAD Cohort I</arm_group_label>
    <arm_group_label>Part 3 (Chronic Hepatitis B [CHB] Participants): MAD Cohort J</arm_group_label>
    <arm_group_label>Part 3 (Chronic Hepatitis B [CHB] Participants): MAD Cohorts F-H</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Capsules or Tablets</description>
    <arm_group_label>Part 1 (Healthy Subjects): Single Ascending Dose (SAD)</arm_group_label>
    <arm_group_label>Part 2 (Healthy Subjects): Multiple Ascending Dose (MAD)</arm_group_label>
    <arm_group_label>Part 3 (Chronic Hepatitis B [CHB] Participants): MAD Cohort I</arm_group_label>
    <arm_group_label>Part 3 (Chronic Hepatitis B [CHB] Participants): MAD Cohort J</arm_group_label>
    <arm_group_label>Part 3 (Chronic Hepatitis B [CHB] Participants): MAD Cohorts F-H</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir Disoproxil Fumarate</intervention_name>
    <description>Tablets</description>
    <arm_group_label>Part 3 (Chronic Hepatitis B [CHB] Participants): MAD Cohort J</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy Subjects&#xD;
&#xD;
               1. Male subjects or female subjects not of childbearing potential between 18 and 45&#xD;
                  years old.&#xD;
&#xD;
               2. Free from clinically significant illness or disease as determined by their&#xD;
                  medical history, physical examination, vital signs, and clinical laboratory test&#xD;
                  results.&#xD;
&#xD;
               3. BMI of 18-32 kg/m2.&#xD;
&#xD;
          -  CHB Subjects:&#xD;
&#xD;
               1. Male or female between 18 and 65 years old.&#xD;
&#xD;
               2. Chronic HBV infection documented as a positive HBsAg, HBV DNA, or HBeAg test at&#xD;
                  least 6 months prior to the Screening Visit, or a historical liver biopsy&#xD;
                  consistent with chronic HBV infection&#xD;
&#xD;
               3. For cohort F, G, H and J:&#xD;
&#xD;
                    1. HBV DNA ≥2,000 IU/mL at Screening (subjects may be either treatment-naïve or&#xD;
                       treatment-experienced but currently off-treatment).&#xD;
&#xD;
                    2. ALT ≤ 5x ULN&#xD;
&#xD;
               4. For Cohort I:&#xD;
&#xD;
                    1. HBV DNA &lt;LLOQ at Screening&#xD;
&#xD;
                    2. Subjects must have been receiving either TAF, TDF, or ETV consistently for&#xD;
                       ≥6 months prior to Day 1 and are willing to continue with the same NA&#xD;
                       treatment through the final study visit.&#xD;
&#xD;
                    3. ALT ≤ 2.5 x ULN&#xD;
&#xD;
               5. HbsAg ≥250 IU/mL at screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  CHB Subjects&#xD;
&#xD;
               1. Advanced fibrosis, cirrhosis or other signs of advanced liver disease as assessed&#xD;
                  by clinical history, ultrasound or FibroScan, or history of cirrhosis or any&#xD;
                  clinically significant medical condition associated with chronic liver disease.&#xD;
&#xD;
               2. Co-infection with HIV or other non-B hepatitis viruses.&#xD;
&#xD;
               3. Any clinically significant or unstable medical condition or illness that could&#xD;
                  confound study findings.&#xD;
&#xD;
               4. Subjects who are unwilling to comply with protocol contraception requirements,&#xD;
                  and female subjects who are pregnant or breastfeeding.&#xD;
&#xD;
               5. Previous treatment with a capsid inhibitor, core inhibitor, or core protein&#xD;
                  assembly modifier [CpAM or CAM]) within 6 months of the Day 1 visit, or prior&#xD;
                  treatment with an HBV-targeted siRNA or antisense oligonucleotide compound at any&#xD;
                  time.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Arbutus Biopharma</last_name>
    <phone>267-469-0914</phone>
    <email>clinicaltrials@arbutusbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arensia Exploratory Medicine</name>
      <address>
        <city>Chisinau</city>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Auckland Clinical Studies</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arensia Exploratory Medicine</name>
      <address>
        <city>Kapitanivka</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Hong Kong</country>
    <country>Moldova, Republic of</country>
    <country>New Zealand</country>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>February 24, 2021</study_first_submitted>
  <study_first_submitted_qc>February 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2021</study_first_posted>
  <last_update_submitted>July 12, 2021</last_update_submitted>
  <last_update_submitted_qc>July 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

